Novavax stock analysis
Want to see NVAX full AI Analyst Report?
Novavax (NVAX) Stock Price & Analysis
NVAX Stock Chart & Stats
- Day’s Range
- $7.43 - $7.98
- 52-Week Range
- $6.25 - $13.39
- Previous Close
- $7.72
- Volume
- N/A
- Average Volume (3M)
- 6.29M
- Market Cap
- $1.23B
- Enterprise Value
- $1.46B
- Total Cash (Recent Filing)
- $622.36M
- Total Debt (Recent Filing)
- $295.26M
- Price to Earnings (P/E)
- ―
- Beta
- 1.50
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.54
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sanofi Partnership Monetization
The Sanofi alliance has demonstrated substantial commercial value through more than $1 billion of cumulative revenue and a new $125 million milestone. Further technology-transfer, launch, and royalty opportunities could provide durable non-product revenue and validate Novavax’s platform.
Cash Runway And Operating Discipline
A multiyear cash runway gives Novavax time to advance its portfolio and absorb uneven vaccine demand without immediate financing pressure. Planned reductions in R&D, SG&A, headcount, and facilities should also improve operating leverage as partner support work winds down.
Validated Matrix-M Platform
Use of Matrix-M in two commercial vaccines provides real-world validation beyond a single COVID product and expands potential applications across infectious disease. Broad partner interest may create additional licensing, supply, and collaboration opportunities over time.
Bears Say
Volatile And Declining Revenue
The sharp reversal from strong annual results to lower TTM revenue shows that Novavax’s earnings base remains highly dependent on changing vaccine demand and contract timing. Negative operating margins indicate current revenue is not yet sufficient to support the cost structure sustainably.
Persistently Negative Shareholders’ Equity
A negative equity position reduces balance-sheet resilience and makes leverage measures less favorable, even when absolute debt is moderate. This limits financial flexibility during weak operating periods and increases dependence on successful milestones, partnerships, or future external funding.
Ongoing Cash Burn
Persistent operating and free-cash-flow losses mean Novavax is consuming liquidity rather than internally funding its business. Even with stated runway, continued burn raises execution pressure and makes future investment capacity more dependent on milestones, product sales, and cost reductions.
Novavax News
Novavax Halts Omicron Booster Study, Raising Fresh Questions for NVAX Investors
Novavax ($NVAX) announced an update on their ongoing clinical study. Novavax has updated a Phase 4 U.S. study called “A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the
NVAX FAQ
What was Novavax’s price range in the past 12 months?
What is Novavax’s market cap?
When is Novavax’s upcoming earnings report date?
How were Novavax’s earnings last quarter?
Is Novavax overvalued?
Does Novavax pay dividends?
What is Novavax’s EPS estimate?
How many shares outstanding does Novavax have?
What happened to Novavax’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Novavax?
What is the TipRanks Smart Score and how is it calculated?
Novavax Stock Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Charles Jacobs
- Employees
- 749
- Website
- www.novavax.com
- Address
- 21 Firstfield Road, Gaithersburg, MD, 20878, US
Novavax (NVAX) Earnings & Revenues
NVAX Company Deck
NVAX Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with substantial progress in Sanofi partnership milestones, commercial activity, cash runway, cost reductions, revenue guidance, Matrix-M demand, and pipeline development. The main challenges were lower quarterly revenue due to declining R&D reimbursement, uncertainty around future COVID market dollars and partner timelines, potential non-cash write-offs, and the early-stage nature of the C. diff and oncology programs. Highlights significantly outweighed the lowlights.
View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |












